Boston Scientific Falls 33% YTD After Trial Data, Pacemaker Recall and EPS Dilution
Boston Scientific shares lost a third year-to-date with a 9% one-day drop after CHAMPION-AF trial showed higher ischemic strokes for Watchman FLX versus blood thinners. The firm cut Q1 guidance, faces a 1.6M-unit pacemaker recall and EPS dilution from its $14.5B acquisition while trading at 18.1x forward earnings.
1. Stock Decline and Trial Data
Boston Scientific shares fell a third year-to-date, including a 9% single-session drop, after CHAMPION-AF trial data showed a slightly higher ischemic stroke rate for the Watchman FLX device versus standard blood thinners, triggering a major analyst downgrade and target cut.
2. Guidance Miss, Recall, and Acquisition Impact
The company lowered Q1 2026 guidance below analyst forecasts, is managing a recall affecting 1.6 million Accolade pacemakers due to battery issues, and expects EPS dilution of $0.06–$0.08 in its first full year post its $14.5 billion Penumbra acquisition.
3. Valuation and Institutional Positioning
Shares trade at 18.1x forward earnings versus a three-year historical average of 26.5x, implying roughly 40% upside, while Allspring Global Investments raised its stake by 6.8% to over 2.17 million shares during the fourth quarter.